Recombinant Carboxypeptidase B

Information

  • Patent Application
  • 20080311619
  • Publication Number
    20080311619
  • Date Filed
    September 26, 2005
    19 years ago
  • Date Published
    December 18, 2008
    16 years ago
Abstract
A nucleic acid coding for pro-carboxypeptidase B (Pro-CPB), comprising three segments A, B and C, wherein at least one of the segments has one of the sequences according to SEQ ID No. 1, 2 or 3.
Description
BACKGROUND

1. Field of the Invention


The present disclosure relates to pro-carboxypeptidase B and carboxypeptidase B and to a process for preparing them.


2. Discussion of the Background Art


Carboxypeptidase B (CPB) is a pancreatic exopeptidase which cleaves by the hydrolysis of peptide linkages at basic amino acids, such as lysine, arginine and ornithine. The cleavage is effected at the C-terminal end of the polypeptides. It is a zinc-containing peptidase (EC 3.4.17.2).


Carboxypeptidase B is formed from pre-pro-carboxypeptidase B, which is enzymatically inactive. From pre-pro-carboxypeptidase B, a signal peptide is cleaved off to obtain a pro-carboxypeptidase B, which is also enzymatically inactive. From the latter, another peptide is cleaved off to obtain the active carboxypeptidase.


The molecular weight of carboxypeptidase B is about 35 kD. It is employed for a wide variety of purposes, especially for the preparation of peptides, such as insulin, and in protein sequence analysis. Carboxypeptidase B is usually purified from porcine pancreas.


The cDNA sequences of human carboxypeptidase B are known.


WO 96/23064 describes a process for the preparation of recombinant rat carboxy-peptidase B. Attempts to express the plasmid described were not successful.


Commercially available carboxypeptidase (purified from natural sources) typically has activities of about 50 to 170 U/mg. One unit (1 U) corresponds to the hydrolysis of 1 mmol of hippuryl-L-Arg per min at 25° C. and at a pH of 7.65.


Carboxypeptidase B purified from natural sources is always contaminated with small amounts of other proteases. Therefore, there is still a need for highly pure carboxypeptidases having an activity as high as possible.


SUMMARY OF THE INVENTION

A novel pro-carboxypeptidase B (pro-CPB) and a novel carboxypeptidase B (CPB), wherein the carboxypeptidases have an enzyme activity of at least 200 U per mg, preferably more than 250 U per mg, more preferably more than 270 U per mg.


The carboxypeptidases are more readily purified. Carboxypeptidase B obtained from porcine pancreas has a purity of 81.6% in reverse-phase HPLC, while the CPB according to the invention has a purity of 97.4%. In gel permeation chromatography, the carboxypeptidases according to the invention have a purity of 99.1% while a carboxypeptidase purified from porcine pancreas has a purity of 77.2%. Surprisingly, the altered structure achieves a higher temperature stability at 40° C. In addition, it shows a higher long-term stability when stored in a liquid form at pH 8.







DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

Therefore, on the one hand, the present disclosure relates to a nucleic acid coding for pro-carboxypeptidase B (Pro-CPB) comprising three segments A, B and C, wherein at least one of the segments has one of the sequences according to SEQ ID No. 1, 2 or 3.


In a preferred embodiment, segment A has the sequence according to SEQ ID No. 1, segment B has the sequence of SEQ ID No. 2, and/or segment C has the sequence according to SEQ ID No. 3.


In a further preferred embodiment, at least two of segments A, B and C respectively correspond to one of the sequences having the SEQ ID No. 1, 2 or 3.


In one embodiment, the remaining segments that do not contain any of sequences 1, 2 or 3 are selected from sequences 4 to 6 or 9 to 11.


In one embodiment, at least one of the segments has one of the sequences according to SEQ ID No. 1, 2 or 3, and the sequences are selected from the sequences 1, 4 and 9 for segment A, from 2, 5 and 10 for segment B, and from 3, 6 and 11 for segment C.


Particularly preferred sequences for the nucleic acid coding for pro-carboxypeptidase B are sequences selected from the group consisting of:

    • SEQ ID No. 1-SEQ ID No. 2-SEQ ID No. 3
    • SEQ ID No. 1-SEQ ID No. 5-SEQ ID No. 6
    • SEQ ID No. 4-SEQ ID No. 2-SEQ ID No. 6
    • SEQ ID No. 4-SEQ ID No. 5-SEQ ID No. 3
    • SEQ ID No. 1-SEQ ID No. 2-SEQ ID No. 6
    • SEQ ID No. 1-SEQ ID No. 5-SEQ ID No. 3
    • SEQ ID No. 4-SEQ ID No. 2-SEQ ID No. 3.


The present disclosure further relates to the pro-carboxypeptidase obtainable by expressing a nucleic acid according to the invention, and to a carboxypeptidase B obtainable by cleaving off the pro sequence of pro-carboxypeptidase B according to the invention. Such a cleavage can be performed, for example, by trypsin.


The present disclosure further relates to an expression vector containing the nucleic acid according to the invention, and to a transformed organism containing the expression vector according to the invention.


The present disclosure further relates to a protein containing an amino acid sequence according to SEQ ID No. 8 with at least 5 mutations selected from the group of D22H, S24N, E25I, R33T, A63T, E69K, C94V, E115Q, K120E, D135E, D137R, N138T, Q168P, D177E, Y184R, A186I, F191L, N194K, N240D, T245S, V246I, V250R, N254D, 1295M, D309N, S314A, G318A, A319T, Y327H, S330K, S337A, N353D, F370Y, A381P, Q384E, V390I, N395S, T397V.


In one embodiment, a Y is appended as amino acid 402.


In a preferred embodiment, the protein according to the present disclosure includes at least seven, more preferably at least ten and most preferably at least fifteen of the above mentioned mutations. The protein may additionally have up to 30 other mutations, deletions or insertions.


Being a recombinant protein, the protein according to the present disclosure is free from contaminations by other natural proteases. In addition, it can be produced in particularly high purity, especially purities of more than 170 U per mg, preferably more than 200 U per mg, more preferably more than 250 U per mg, and most preferably more than 280 U per mg.


The present disclosure further relates to a process for expressing pro-CPB, comprising the steps of:

    • culturing a transformed organism;
    • inducing the expression;
    • purifying the pro-CPB;


      and to a process for expressing carboxypeptidase B, comprising the steps of:
    • culturing a transformed organism according to claim 10;
    • inducing the expression;
    • activation by cleaving the pro-CPB into CPB;
    • purifying the CPB.


The present invention further relates to a carboxypeptidase having the sequence according to SEQ ID No. 7, preferably with a maximum of 30 mutations, deletions or insertions.


“Mutation” means an exchange of an amino acid for another, “insertion” means the additional introduction of a further amino acid, and “deletion” means the removal of an amino acid.


A particularly preferred expression system is Pichia pastoris. However, in principle, other usual expression systems, such as the Baculovirus system in insect cells, or expression in mammal cells may also be employed. The use of the Pichia expression system has been described, for example, in U.S. Pat. No. 5,102,789, which is included herein by reference.


The nucleic acids according to the present disclosure can be synthesized, for example, by chemical synthesis in fragments, and the fragments subsequently ligated. The proteins according to the present disclosure can then be obtained by expressing the corresponding nucleic acid. The nucleic acid may also be obtained by site-directed mutagenesis from the known cDNA sequence of CBP. Methods thereof are described, for example, in The Journal of Biological Chemistry, 174 (1999), 19925-19933, which is included herein by reference.


The present disclosure will be further illustrated by the following further Examples.


The genes were cloned into the following vectors:



















Pichia pastoris:

pKINTEX, pKEXTEX, pPiczα




E. coli:

Tuner(DE3)pET22-OMPA




Arxula adeninovirans:

pAL-ALEU2m-GAA 1.










The highest expression rates were achieved in Pichia pastoris: pKEXTEX-npproCPB.


Culturing Method

A fed-batch method and a continuous method were developed. In these methods, about 200 mg/l of npproCPB was secreted into the medium.


Fed-Batch Culture
Fermentation Medium (for 1 l):
Hexaphosphate Medium





    • 25 g of sodium hexametaphosphate

    • 9 g of ammonium sulfate





Glycerol Salt Medium

45.6 g of glycerol (86%)


18.2 g of potassium sulfate


14.9 g of magnesium sulfate heptahydrate


0.9 g of calcium sulfate dihydrate


PTM1 (trace elements) 1 ml/l
















Glycerol feed (1 l)
ad 1000 ml with
autoclave


314 g (86%)
dist. water


of glycerol




after cooling, addition




of 9 ml of sterile PTM1


Methanol feed (1 l)

addition of 12 ml


1 l of methanol

of sterile PTM1









Culturing Conditions
















Temperature
28° C.



Stirring speed, rotations
500 to 1000 rpm


per minute


Culturing time
90.1 to 138.6 hours


Gas supply
0.8 to 2 vvm
air


Starting volume culture
2 to 8 l
medium and inoculation


broth

culture


Inoculation volume
10% of total starting
shaking culture



volume


Oxygen partial pressure
6 to 100%


pH value
4.4 to 7.3









Course of Culture
















Glycerol
Start:
at an optical density OD600


addition

of the culture broth (absorption at




600 nm) of between 15 and 140



Feeding rate:
between 0.4 and 1.8 ml/min of




glycerol feed



Amount fed:
between 4.2 and 16.6% of the starting




volume


Methanol
Start:
at an OD600 of between


addition

50 and 195



Feeding rate:
between 0.04 and 0.2 ml/min for metha-




nol control between 0.1 and 3% methanol




content in the culture broth


Termination of
OD600:
between 144.2 and 510


culture









Continuous Culture

Medium components of continuous feed (1 l)
















9.8 ml of phosphoric acid




(75%)


0.2 g of calcium chloride


dihydrate


6 g of potassium sulfate


2.28 g of magnesium sulfate


heptahydrate


1.35 g of potassium hydroxide
in 500 ml of dist. water


1 ml of Struktol SB2122

autoclave


5.4 mg of biotin in solution

sterile-filtered


2.7 ml of PTM1

sterile-filtered


6 ml of ammonia (25%)


239 ml of methanol



ad 1000 ml with



autoclaved distilled



water









Course of Culture
















Glycerol addition
Start:
at OD600 16.5



Feeding rate:
between 1.4 ml/min glycerol feed



Amount fed:
21.8% of starting volume


Methanol addition
Start:
at OD600 126.8



Feeding rate:
0.23 ml/min



Amount fed:
9% of starting volume


Continuous feed
Start:
at OD600 130.1



Feeding rate:
between 20 and 200 ml/h









Processing Method

1st step: Activation of npproCPB by trypsin cleavage


2nd step: anion-exchange chromatography—DEAE-Sephacel


3rd step: hydrophobic interaction chromatography—butyl-sepharose


This method yields a pure npCPB.


Activation of pronpCPB by Means of Trypsin Cleavage


















Trypsin from
porcine pancreas 1645 U/mg or




porcine pancreas 15,000 U/mg or




bovine pancreas 9,280 U/mg



Concentration ratios
between 1:1 and 1:1000



(trypsin:pronpCPB)



pH values
between pH 6.5 and pH 8.5



Cleavage time
between 10 min and 17 hours



Temperature
between 4 and 30° C.



Time of activation in the
untreated culture supernatant



processing
after PEG precipitation and dialysis




after DEAE chromatography










Anion-Exchange Chromatography


















Anion-exchange gel
DEAE-Sephacel or Q-Sepharose



Column volume
5 to 500 ml



Elution buffer
20 mM Tris/acetate + 0.1 mM of ZnCl2




pH 7.5 or pH 8



Continuous gradient
0 to 250 mM of NaCl or 0 to 500 mM




of NaCl



Step gradient
between 500 mM and 1000 mM NaCl



Gradient length
between 1 and 5 column volumes



Loading (CPB/ml of
between 10 and 64 U/ml



anion-exchange gel)










Hydrophobic Interaction Chromatography (HIC)


















HIC gel
Toyopearl Butyl 650M



Column volume
between 25 and 50 ml



Elution buffer
20 mM of Tris/acetate + 0.1 mM of




ZnCl2 pH 7.5



Continuous gradient
1000 mM to 0 mM of ammonium




sulfate



Step gradient
20 mM of Tris/acetate + 0.1 mM of




ZnCl2 pH 7.5



Gradient length
between 4 and 10 column volumes



Loading (CPB/ml
between 29.2 and 183 U/ml



of HIC gel)










Enzyme Activity

To determine the specific activity of the recombinant carboxypeptidase B (npCPB) and the carboxypeptidase B from porcine pancreas (pigCPB), the following procedure is employed. First, the volume activity of the CPB is determined. as the substrate solution, 0.015 mol of hippurylarginine (Sigma company) is dissolved in 0.05 M Tris/HCl buffer, pH 7.8. Further, a 50 mM Tris/HCl buffer, pH 7.8, is needed. The reaction solution consists of 0.5 ml of Tris buffer, 0.1 ml of the substrate solution and 0.385 ml of distilled water. The reaction is started with 17 μl of CPB enzyme solution. The photometric measurement (ΔE) is effected for 1 min in a silica glass cuvette at a layer thickness of 0.5 cm and at a temperature of 25° C. and at a wavelength of λ=254 nm. The CPB activity is calculated according to the following formula.







CPB




[

U


/


ml

]

=


Δ






E
·
1002
·
dilution




0.349
·
0.5
·
enzyme






solution





employed






The related protein concentration of the enzyme solution is determined by photometry at a wavelength of 280 nm in a silica glass cuvette having a layer thickness of 1 cm and a temperature of between 20 and 25° C. At first, the blank is established by measuring only the absorption of the sample buffer (E(blank)). The sample buffer consists of 0.033 M Tris/HCl, pH 8.0. Then, 0.05 ml of CPB solution is diluted in 3 ml of sample buffer, and the absorption is also determined (E(sample)). The protein concentration is calculated from the following formula.







Protein






content




[

mg


/


ml

]


=



10







g
/
l

·
Δ






E






(
sample
)


21.4

·
61






ΔE(sample)=E(sample)−E(blank)

















Protein
Specific


Enzyme
Activity
content
activity







npCPB
 92.6 U/ml
0.31 mg/ml
298.7 U/mg


pigCPB (archive
244.4 U/ml
0.94 mg/ml
260.0 U/mg


28754, Merck


company)








Claims
  • 1. A nucleic acid coding for pro-carboxypeptidase B (Pro-CPB), comprising three segments A, B and C, wherein at least one of the segments has one of the sequences according to SEQ ID No. 1, 2 or 3.
  • 2. The nucleic acid according to claim 1, characterized in that segment A has the sequence according to SEQ ID No. 1, segment B has the sequence of SEQ ID No. 2, and/or segment C has the sequence according to SEQ ID No. 3.
  • 3. The nucleic acid according to claim 1, wherein at least two of segments A, B and C have one of the sequences according to SEQ ID No. 1, 2 or 3.
  • 4. The nucleic acid according to claim 1, wherein the remaining segments are selected from sequences of SEQ ID No. 4, 5 or 6.
  • 5. The nucleic acid according to claim 1, wherein the sequence is selected from the group consisting of: SEQ ID No. 1-SEQ ID No. 2-SEQ ID No. 3SEQ ID No. 1-SEQ ID No. 5-SEQ ID No. 6SEQ ID No. 4-SEQ ID No. 2-SEQ ID No. 6SEQ ID No. 4-SEQ ID No. 5-SEQ ID No. 3SEQ ID No. 1-SEQ ID No. 2-SEQ ID No. 6SEQ ID No. 1-SEQ ID No. 5-SEQ ID No. 3SEQ ID No. 4-SEQ ID No. 2-SEQ ID No. 3.
  • 6. A pro-carboxypeptidase obtainable by expressing a nucleic acid coding for pro-carboxypeptidase B (Pro-CPB), comprising three segments A, B and C, wherein at least one of the segments has one of the sequences according to SEQ ID No. 1, 2 or 3.
  • 7. A carboxypeptidase B obtainable by cleaving off the pro sequence of a pro-carboxypeptidase obtainable by expressing a nucleic acid coding for pro-carboxypeptidase B (Pro-CPB), comprising three segments A, B and C, wherein at least one of the segments has one of the sequences according to SEQ ID No. 1, 2 or 3 trypsin.
  • 8. The carboxypeptidase according to claim 7, having an enzyme activity of at least 200 U/mg.
  • 9. An expression vector containing the nucleic acid coding for pro-carboxypeptidase B (Pro-CPB), comprising three segments A, B and C, wherein at least one of the segments has one of the sequences according to SEQ ID No. 1, 2 or 3.
  • 10. A transformed organism containing the expression vector containing the nucleic acid coding for pro-carboxypeptidase B (Pro-CPB), comprising three segments A, B and C, wherein at least one of the segments has one of the sequences according to SEQ ID No. 1, 2 or 3.
  • 11. A process for expressing a pro-carboxypeptidase obtainable by expressing a nucleic acid coding for pro-carboxypeptidase B (Pro-CPB), comprising three segments A, B and C, wherein at least one of the segments has one of the sequences according to SEQ ID No. 1, 2 or 3, comprising the steps of: culturing a transformed organism containing the expression vector containing the nucleic acid coding for pro-carboxypeptidase B (Pro-CPB), comprising three segments A, B and C, wherein at least one of the segments has one of the sequences according to SEQ ID No. 1, 2 or 3;inducing the expression; andpurifying the pro-carboxypeptidase.
  • 12. A process for expressing carboxypeptidase B obtainable by cleaving off the pro sequence of a pro-carboxypeptidase obtainable by expressing a nucleic acid coding for pro-carboxypeptidase B (Pro-CPB), comprising three segments A, B and C, wherein at least one of the segments has one of the sequences according to SEQ ID No. 1, 2 or 3 by trypsin, said process comprising the steps of: culturing a transformed organism containing the expression vector containing the nucleic acid coding for pro-carboxypeptidase B (Pro-CPB), comprising three segments A, B and C, wherein at least one of the segments has one of the sequences according to SEQ ID No. 1, 2 or 3;inducing the expression;activation by cleaving the pro-CPB into carboxypeptidase B; andpurifying the carboxypeptidase B.
  • 13. A pro-carboxypeptidase having the sequence according to SEQ ID No. 7.
  • 14. The pro-carboxypeptidase according to claim 13, having a maximum of 30 mutations, deletions or insertions.
  • 15. A protein having an amino acid sequence according to SEQ ID No. 8 with at least 5 mutations selected from the group of D22H, S24N, E25I, R33T, A63T, E69K, C94V, E115Q, K120E, D135E, D137R, N138T, Q168P, D177E, Y184R, A186I, F191L, N194K, N240D, T245S, V246I, V250R, N254D, 1295M, D309N, S314A, G318A, A319T, Y327H, S330K, S337A, N353D, F370Y, A381P, Q384E, V390I, N395S, T397V.
  • 16. The protein according to claim 15, having a maximum of 30 further mutations, deletions or insertions.
Priority Claims (1)
Number Date Country Kind
04104696.2 Sep 2004 EP regional
PCT Information
Filing Document Filing Date Country Kind 371c Date
PCT/EP05/54806 9/26/2005 WO 00 7/21/2008